Harvard Bioscience (NASDAQ:HBIO) Upgraded at Zacks Research

Zacks Research upgraded shares of Harvard Bioscience (NASDAQ:HBIO) to a hold rating in a report issued on Thursday,Zacks.com reports.

Several other brokerages have also recently weighed in on HBIO. Weiss Ratings reiterated a “sell (d-)” rating on shares of Harvard Bioscience in a report on Monday, December 8th. Benchmark lowered their price objective on shares of Harvard Bioscience from $3.00 to $2.00 and set a “speculative buy” rating for the company in a research note on Wednesday, September 10th. Finally, Wall Street Zen upgraded shares of Harvard Bioscience from a “hold” rating to a “buy” rating in a report on Monday, November 17th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $2.00.

Harvard Bioscience Price Performance

Shares of HBIO stock opened at $0.74 on Thursday. The company has a market capitalization of $33.03 million, a P/E ratio of -0.61 and a beta of 1.53. The company’s 50-day simple moving average is $0.58 and its two-hundred day simple moving average is $0.51. Harvard Bioscience has a one year low of $0.28 and a one year high of $2.30.

Hedge Funds Weigh In On Harvard Bioscience

A number of large investors have recently added to or reduced their stakes in the company. Nuveen LLC purchased a new stake in Harvard Bioscience during the first quarter valued at approximately $79,000. Williams & Novak LLC grew its holdings in Harvard Bioscience by 37.0% in the second quarter. Williams & Novak LLC now owns 106,570 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 28,800 shares during the last quarter. Deutsche Bank AG increased its position in shares of Harvard Bioscience by 221.1% during the first quarter. Deutsche Bank AG now owns 75,985 shares of the medical instruments supplier’s stock worth $43,000 after purchasing an additional 52,319 shares in the last quarter. AMH Equity Ltd lifted its holdings in shares of Harvard Bioscience by 3.6% during the 2nd quarter. AMH Equity Ltd now owns 3,508,703 shares of the medical instruments supplier’s stock valued at $1,557,000 after purchasing an additional 121,348 shares during the last quarter. Finally, Pasadena Private Wealth LLC boosted its position in shares of Harvard Bioscience by 23.2% in the 2nd quarter. Pasadena Private Wealth LLC now owns 243,911 shares of the medical instruments supplier’s stock worth $108,000 after purchasing an additional 45,872 shares in the last quarter. 80.87% of the stock is currently owned by institutional investors.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.